CreditReports.dk
HomeScreen companies

AKI Therapeutics A/S Financials, key figures and credit report

CVR number: 37509736 Established 2016 Industry: 21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
Company contact details
Slotsmarken 12, 2970 Hørsholm
Gross profit — FY 2025
EBIT -1 232 059.0 kDKK FY 2025 +36.7% vs 2024
Net debt -5 709.0 kDKK FY 2025 +94.5% vs 2024
Quick ratio 0.4 FY 2025 -0.3 vs 2024

Company information

Official name
AKI Therapeutics A/S
Established
2016
Company form
Limited company
Industry
  • Expand more icon21Manufacture of basic pharmaceutical products and pharmaceutical preparations

Data sources and methodology

The information about AKI Therapeutics A/S combines official Danish company and financial-statement data with indicators calculated by Valuatum Oy.

Company information

Name, CVR number, address, industry and legal form are based on the Danish Central Business Register (CVR).

CVR / Virk

Annual accounts

Financial figures come from annual reports published through the Danish Business Authority. The latest financial year used is 2025.

Key figures and credit risk

Valuatum Oy calculates financial ratios, comparisons and credit-risk indicators from the available accounts. The results support analysis and do not constitute a standalone credit decision.

Valuatum Oy

About AKI Therapeutics A/S

AKI Therapeutics A/S (CVR number: 37509736) is a company from HØRSHOLM. The company recorded a gross profit of 0 kDKK in 2025. The operating profit was -1232.1 mDKK, while net earnings were -1593.9 mDKK. The profitability of the company measured by Return on Assets (ROA) was -64.7 %, which can be considered poor and Return on Equity (ROE) was -234.6 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 33.7 %, a level that can be considered to be low. This means a higher proportion of debt in its capital structure, indicating a greater reliance on borrowed funds. AKI Therapeutics A/S's liquidity measured by quick ratio was 0.4 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.

Financial information

See financials

Gross profit (kDKK)

EBIT (kDKK)

Profitability

Solidity

Key figures (kDKK)

See financials
2021
2022
2023
2024
2025
Volume
Net sales
Gross profit
EBIT-1 864.48-1 312.74-2 022.33-1 946 770.00-1 232 059.00
Net earnings-1 523.62-1 117.35-1 708.69-1 960 091.00-1 593 852.00
Shareholders equity total3 572.632 455.28746.59806 760.00551 898.00
Balance sheet total (assets)4 731.533 321.361 992.952 168 755.001 639 948.00
Net debt-2 828.16-1 242.37- 225.56- 103 691.00-5 709.00
Profitability
EBIT-%
ROA-56.0 %-32.6 %-74.4 %- 179.4 %-64.7 %
ROE-82.6 %-37.1 %- 106.7 %- 485.5 %- 234.6 %
ROI- 103.1 %-42.0 %- 110.9 %- 335.6 %- 121.9 %
Economic value added (EVA)-1 414.95-1 279.43-1 865.25-1 713 138.30-1 200 008.58
Solvency
Equity ratio75.5 %73.9 %37.5 %37.2 %33.7 %
Gearing
Relative net indebtedness %
Liquidity
Quick ratio3.32.90.70.70.4
Current ratio3.32.90.70.70.4
Cash and cash equivalents2 828.161 242.37225.56103 691.005 709.00
Capital use efficiency
Trade debtors turnover (days)
Net working capital %

Variable visualization

ROA FY 2025
-64.7%
Rating 0/100
-20%
0%
4%
11%
24%
60%
Graph showing the distribution of the variable
Equity ratio FY 2025
33.7%
Rating 29/100
-1%
21%
50%
81%
99%
100%
Graph showing the distribution of the variable

Credit Risk Report

Affordable credit risk report
for basic company risk checks.

Check the creditworthiness of AKI Therapeutics A/S before offering payment terms. The report combines financial figures, risk scores, credit rating, bankruptcy risk and a credit-limit recommendation in one PDF.

AI Credit Risk Report

The core credit-risk figures,
explained with AI.

The AI Credit Risk Report contains the same core financial figures and risk measures as the Credit Risk Report. It also provides written analysis of the company's finances, risks, repayment capacity and assets, together with relevant context from web searches.

  1. 01 Includes the same financial figures, risk scores, credit rating and bankruptcy risk as the Credit Risk Report.
  2. 02 AI complements the analysis with web searches and brings in the relevant company and operating-environment observations.
  3. 03 The written analysis is more precise, more readable and better suited to decision-making.
… / report

Company-specific, AI-assisted credit risk report in PDF format.

For larger customers

Reports can be tailored to your own credit process: content structure, peer groups, risk thresholds, delivery method and AI-analysis weightings can all be adapted to your needs.
Ask about a tailored solution: contact@creditreports.dk

The report is intended for an initial financial assessment. · The final credit decision and any further verification are always the user's responsibility. · One-time payment, no subscription.

AI report sample

1 example
Example: JYSK A/S Open demo

What the report includes

8 sections
Financial figures
Risk scores
Credit rating
Bankruptcy risk
AI web-search highlights
Written risk analysis
Conclusions
Ratio appendices

Roles

Companies in the same industry

Page generated